Maoxing Biotech Secures Tens of Millions in Angel+ Funding to Advance Allogeneic CAR-T Therapies for Solid Tumors

VCBeat has learned that Jiangsu Maoxing Technology Co., Ltd. (hereinafter referred to as "Maoxing Technology"), a globally leading R&D company specializing in off-the-shelf CAR-T therapies for solid tumors, recently announced the successful closure of a tens-of-millions RMB Angel+ financing round. The round was led by Haibang Medical Fund, with Hongfeng Investment participating as a co-investor, and Haoyue Capital served as the exclusive financial advisor for this round.

Suzhou Maoxing Biotechnology Co., Ltd. is a universal CAR-T company specializing in brain tumors, with its headquarters in Suzhou. The company features a unique universal CAR-T development platform that effectively addresses two major pain points in the field: graft-versus-host disease (GvHD) and host-versus-graft (HvG). The allogeneic CAR-T cells developed by the company achieve long-term persistence in patients and have already demonstrated excellent therapeutic efficacy.

In an investigator-initiated clinical trial, three patients with recurrent advanced glioblastoma treated with the company’s lead pipeline therapy achieved a 100% objective response rate. Prioritizing original research and adhering to the "in China, for Global" philosophy, Maoxing Biotech remains committed to developing innovative products with a global strategic vision. The company has currently established multiple target-specific pipelines for brain tumors and plans to conduct registration trials in both China and the United States in the future.

Dr. Shang Xiaoyun, Founder of Maoxing Biotechstated, "The off-the-shelf CAR-T cell therapy developed by Maoxing Biotech innovatively combines gene editing technology with immunotherapy, effectively reducing treatment costs and achieving superior therapeutic outcomes. Our pipeline has yielded promising results in investigator-initiated trials, and we are actively preparing to submit applications for registration-based clinical trials in both China and the United States. We aim to accelerate its development into a new drug that benefits patients worldwide. On behalf of the founding team, I would also like to thank our new and existing investors for their recognition and trust. We will certainly live up to your expectations and forge ahead with determination."

Mr. Shan Jialiang, Managing Partner of Haibon Healthcare Fundstated, "Currently, there are no effective drugs for high-grade gliomas, representing a clear unmet clinical need. Maoxing's universal CAR-T platform features proprietary technologies and strategies, and preliminary results in patients with late-stage recurrent gliomas have already been highly encouraging, bringing hope to these patients. Maoxing has established multiple brain tumor pipelines, and its development potential is highly promising. We are willing to accompany the Maoxing team as we grow together."

Mr. Lou Guoqiang, Founding Partner of Hongfeng Investmentstated, "Maoxing Biotechnology's CRISPR-based universal CAR-T therapy targeting solid tumors represents a breakthrough in the current CAR-T innovation research field, which has predominantly focused on hematological malignancies as the primary indication. Favorable efficacy has already been observed in investigator-initiated clinical trials. Hongfeng Investment is delighted to participate in Maoxing Biotechnology's pioneering work in addressing diseases with unmet clinical needs, particularly in the immunotherapy of gliomas. We are highly confident that Dr. Shang Xiaoyun and his team will ultimately achieve positive outcomes through their dedicated efforts."

Mr. Li Yishi, Partner at Haoyue Capitalstated, “We are honored to assist Maoxing Technology in completing this round of financing. Universal CAR-T can address many of the limitations of existing CAR-T therapies and represents a prevailing trend in the cell therapy sector. However, overcoming GvHD and HvGR remains an unavoidable challenge for every R&D enterprise. Maoxing Technology boasts a proprietary universal CAR-T R&D platform that employs novel strategies to simultaneously address both GvHD and HvGR. This approach achieves exceptional long-term persistence of the infused cells alongside outstanding safety, which has been robustly validated in clinical settings. We believe that, with financial backing, Maoxing Technology will continue to lead the R&D of universal CAR-T for solid tumors and deliver ongoing innovative breakthroughs. We are confident in our ability to support Maoxing Technology in its subsequent financing rounds and accompany our client on its path to rapid growth.”

Haibang Fenghua was initiated and established by Zhejiang Haibang Investment—a well-known equity investment institution in Zhejiang Province—alongside its entire investment management team. We adhere to the investment philosophy of "Technology + Talent," firmly believe that technology transforms the world, and are committed to supporting entrepreneurs who harbor grand visions and possess strong entrepreneurial spirits. The Haibang Medical Fund is a specialized fund under Haibang Fenghua dedicated to equity investments in the life and health sector. It has invested in over 50 enterprises across fields such as innovative drugs, pharmaceutical development service platforms, medical devices, high-value consumables, diagnostic reagents, and digital healthcare. The fund has backed and cultivated a portfolio of high-quality medical companies, including New Horizon Health, Aotai Biotechnology, Zhiyuan Medical, Heze Medical, MicroTech Medical, GenFleet Therapeutics, Xianweida Biotech, Jianhai Technology, DeKang Medical, MinFound Medical, Ruili Technology, Yiliankang, and Xining Testing.

Hongfeng Investment serves as the supporting fund manager for the Ningbo Hangzhou Bay Life Science Park BioVillage, located on a core plot within the High-End Industrial Zone of Ningbo Qianwan New Area. Covering an area of 100 mu (approximately 6.67 hectares), the park features a planned total gross floor area of approximately 78,000 square meters, comprising biopharmaceutical startup incubators, standalone corporate buildings, and other facilities. Hongfeng Investment focuses on the life sciences and healthcare sector, with a particular emphasis on early-stage innovative biopharmaceutical R&D enterprises.

Capital Healthcare, founded in January 2014, is committed to bridging China’s healthcare sector with capital markets. Its research and transaction coverage spans multiple specialized segments, including innovative medical devices, biopharmaceuticals, IVD and precision medicine, healthcare services, and smart healthcare. The team comprises senior investment bankers with years of deep expertise in China’s healthcare industry. They closely track healthcare investment market dynamics and long-term trends, publishing weekly healthcare investment reports and thematic research studies that interpret emerging policies and frontier developments from the Capital Healthcare perspective.